Promoter holding
64.27%
PB
Plenum Biotech Private Limited - Due diligence report
A 360° intelligence report on Spa Newtraceuticals Pharma: trust score, financial health, credit view, compliance, directors, growth and dist…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Spa Newtraceuticals Pharma — 360° Intelligence Report
Generated from MCA filings & public records84/100
Trust Score
Low Risk
Spa Newtraceuticals Pharma is assessed as Low Risk with a Trust Score of 84/100. Spa Newtraceuticals Pharma is an active private limited indian non-government company incorporated in 2012, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.
Report generated on 10 Jul 2026 from the latest processed filings. Plenum Biotech Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
93/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Profitable - internal accruals available.
Charges position: 1 open (2.45 cr) · 1 satisfied (40.00 Lakh).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Canara Bank | 1 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
Compliance Score: 93/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 1 court forum(s).
- 1 active GST registration(s).
Legal cases on record (1)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| NEERAJ SHARDA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAHUL KHOSLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 3 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 75 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
Operating for 14+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 24% in a year.
1 open charge(s) registered - assets are encumbered.
1 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence82/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment62/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 2.45 cr already registered.
- Compliance record supports lending.
Investor view76/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 2 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 14 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
04 Jul 2023
Charge satisfied
Hdfc Bank Limited
31 Mar 2023
Share transfer (FY 2023)
25000.00000000 shares to SIMRAN SHARDA
07 Nov 2022
Charge created
Canara Bank - 2.45 cr
27 Dec 2021
Charge created
Hdfc Bank Limited - 40.00 Lakh
30 Sep 2016
Director ceased
RAHUL KHOSLA
31 Mar 2016
Share transfer (FY 2016)
12500.00000000 shares to NEERAJ
Share transfer (FY 2016)
12500.00000000 shares to MEENAKSHI
02 Dec 2015
Director ceased
VIKAS SHARMA
01 Dec 2015
Director appointed
RAHUL KHOSLA (Director)
18 Feb 2013
Securities allotted
40000.00 Equity Shares - 4.00 Lakh raised
27 Mar 2012
Incorporated
Registered with Roc Chandigarh
Director appointed
NEERAJ SHARDA (Director)
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Icons Print Media Private Limited | U74900MH2012PTC237058 | Mumbai, Maharashtra, India |
| Logotech Clothing Private Limited | U18101WB2002PTC094426 | Kolkata, West Bengal, India |
| Nugabest Medical India Private Limited | U24299DL2018PTC341340 | New Delhi, Delhi, India |
| Shree Shakti Vyapaar Private Limited | U36999WB2005PTC103375 | Kolkata, West Bengal, India |
| Vdb Automobile Private Limited | U50300HR2021PTC098460 | Karnal, Haryana, India |
| Nexia Global Private Limited | U51909DL2017PTC313999 | Delhi, Delhi, India |
| Mrinal Nuts Processing Private Limited | U15400MP2020PTC051090 | Tehsil Sanwer, Madhya Pradesh, India |
| Busway Electric India Private Limited | U51909WB2022PTC255088 | Kolkata, West Bengal, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Spa Newtraceuticals Pharma before audits and certifications: compliance score 93/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Spa Newtraceuticals Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Spa Newtraceuticals Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Spa Newtraceuticals Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Spa Newtraceuticals Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Spa Newtraceuticals Pharma an active company?
Spa Newtraceuticals Pharma has MCA status “Active” with a compliance score of 93/100 (Low Risk).
Is Spa Newtraceuticals Pharma financially healthy?
Spa Newtraceuticals Pharma has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Spa Newtraceuticals Pharma?
Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Spa Newtraceuticals Pharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.
Does Spa Newtraceuticals Pharma have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.
Is Spa Newtraceuticals Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 93/100 (Low Risk).
Is it risky to lend to Spa Newtraceuticals Pharma?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
